Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination
Ghada A. Badawi, Rehab M. El-Sayed, Mohamed N. Fawzy · 2026
Read Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination by Ghada A. Badawi, Rehab M. El-Sayed, Mohamed N. Fawzy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13558365.txt.
Description
Ghada A. Badawi, Rehab M. El-Sayed, and Mohamed N. Fawzy reframed in 2026 multiple sclerosis as a disease of cellular fuel use as much as of misdirected immunity. Modern immune drugs control relapses yet fail to stop slow progression or repair lost myelin. Their review argues that how immune and nerve cells power themselves decides whether they inflame or protect, and that this programming can be adjusted.
Attacking immune cells run on fast sugar burning, guided by growth switches, while calming regulatory cells and myelin repair crews rely on fat burning and efficient respiration. Two established sclerosis drugs turn out to act partly through these fuel pathways, which supports the idea. The authors survey deliberate metabolic strategies, from blocking glutamine use in aggressive cells to metformin-like agents that may aid remyelination, and to supplements that recharge cellular batteries.
Catalog record
| CREATOR | Ghada A. Badawi, Rehab M. El-Sayed, Mohamed N. Fawzy |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 101 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |